Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population DOI Creative Commons

Min Zhao,

Rebecca Slotkin, Amar H. Sheth

и другие.

Clinical Infectious Diseases, Год журнала: 2022, Номер 76(3), С. e391 - e399

Опубликована: Май 31, 2022

Abstract Background We studied whether comorbid conditions affect strength and duration of immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccination in a US-based, adult population. Methods Sera (before BNT162b2 vaccination) were tested serially up to 12 months doses vaccine for SARS-CoV-2-anti-Spike neutralizing capacity by pseudotyping assay 124 individuals; titers correlated clinical variables with multivariate regression. Postbooster (third dose) effect was measured at 1 3 72 88 subjects, respectively. Results After completion primary series, antibody half maximal inhibitory concentration (IC50) values high month (14-fold increase from prevaccination), declined 6 (3.3-fold increase), increased postbooster (41.5-fold increase). Three postbooster, IC50 decreased disease (COVID)-naïve individuals (18-fold increase) prior COVID 2019 (COVID-19+) (132-fold Age >65 years (β = −0.94, P .001) malignancy −0.88, .002) reduced response month. Both neutralization durability months, respectively, negatively affected end-stage renal ([β −1.10, .004]; [β −0.66, .014]), diabetes mellitus −0.57, .032]; −0.44, .028]), systemic steroid use −0.066, −0.55, .037]). robust against WA-1 B.1.617.2. COVID-19 2.9, < .0001), −0.68, .03), regardless infection status. Conclusions Multiple factors the series vaccination, but not dose strength. Malignancy associated lower booster-dose infection, suggesting need clinically guided regimens.

Язык: Английский

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development DOI Creative Commons
Miao-Miao Zhao, Weili Yang, Fangyuan Yang

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2021, Номер 6(1)

Опубликована: Март 27, 2021

To discover new drugs to combat COVID-19, an understanding of the molecular basis SARS-CoV-2 infection is urgently needed. Here, for first time, we report crucial role cathepsin L (CTSL) in patients with COVID-19. The circulating level CTSL was elevated after and positively correlated disease course severity. Correspondingly, pseudovirus increased expression human cells vitro ACE2 transgenic mice vivo, while overexpression, turn, enhanced cells. functionally cleaved spike protein virus entry, as evidenced by overexpression knockdown application inhibitor vivo. Furthermore, amantadine, a licensed anti-influenza drug, significantly inhibited activity prevented both Therefore, promising target anti-COVID-19 drug development.

Язык: Английский

Процитировано

453

SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19 DOI Open Access
Evgeni Gusev, Alexey Sarapultsev, Л. В. Соломатина

и другие.

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(3), С. 1716 - 1716

Опубликована: Фев. 2, 2022

The review aims to consolidate research findings on the molecular mechanisms and virulence pathogenicity characteristics of coronavirus disease (COVID-19) causative agent, severe acute respiratory syndrome 2 (SARS-CoV-2), their relevance four typical stages in development viral infection. These are invasion; primary blockade antiviral innate immunity; engagement virus’s protection against factors adaptive acute, long-term complications COVID-19. invasion stage entails recognition spike protein (S) SARS-CoV-2 target cell receptors, namely, main receptor (angiotensin-converting enzyme 2, ACE2), its coreceptors, potential alternative receptors. presence a diverse repertoire receptors allows infect various types cells, including those not expressing ACE2. During second stage, majority polyfunctional structural, non-structural, extra proteins synthesizes infected cells involved blockage immunity. A high degree redundancy systemic action characterizing these pathogenic overcome at initial invasion. third includes passive active virus from immunity, overcoming barrier function focus inflammation, generalization body. fourth is associated with deployment variants SARS-CoV-2’s ability induce autoimmune autoinflammatory pathways tissue both immunosuppressive hyperergic inflammation critical this

Язык: Английский

Процитировано

221

Medicinal Plants and Isolated Molecules Demonstrating Immunomodulation Activity as Potential Alternative Therapies for Viral Diseases Including COVID-19 DOI Creative Commons
Hassan A. Alhazmi, Asim Najmi, Sadique A. Javed

и другие.

Frontiers in Immunology, Год журнала: 2021, Номер 12

Опубликована: Май 13, 2021

Plants have been extensively studied since ancient times and numerous important chemical constituents with tremendous therapeutic potential are identified. Attacks of microorganisms including viruses bacteria can be counteracted an efficient immune system therefore, stimulation body's defense mechanism against infections has proven to effective approach. Polysaccharides, terpenoids, flavonoids, alkaloids, glycosides, lactones the phytochemicals, reported primarily responsible for immunomodulation activity plants. These phytochemicals may act as lead molecules development safe immunomodulators remedies prevention cure viral diseases. Natural products known modulate in nonspecific ways. A number plant-based principles identified isolated which justify their use traditional folklore medicine form basis further specified research. The aim current review is describe highlight certain plants along bioactive constituents. Relevant literatures recent years were searched from commonly employed scientific databases on ethnopharmacological use. Most displaying considerable summarized possible mechanisms. discussions shall hopefully elicit attention researchers encourage studies these therapy management infectious diseases, ones such COVID-19.

Язык: Английский

Процитировано

109

Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity DOI Open Access
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma

и другие.

Reviews in Medical Virology, Год журнала: 2021, Номер 32(2)

Опубликована: Июнь 27, 2021

Summary Newly arising variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are now a threat to global public health and creating COVID‐19 surges in different countries. At the same time, there is limited knowledge about these emerging variants. Even if research data available, it varyingly scattered. In this review, we have discussed appearance significant alarming SARS‐CoV‐2 entire world. The study also discusses properties substantial variant concern (VOC) such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 (Epsilon) B.1.429 (Epsilon). characteristic some interest (VOI) like B.1.525 (Eta), B.1.526 (Iota) (sublineage B.1.526.1), B.1.617 (sublineages B.1.617.1 (Kappa), B.1.617.2 (Delta) B.1.617.3), P.2 (Zeta), P.3 (Theta), B.1.616 been discussed. Here, explained essential mutations for VOC VOI K417T/N, L452R, E484K, N501Y, D614G P681R. Consecutively, highlighted crucial clinical characteristics variants, transmissibility, infectivity, re‐infectivity, immune escape, vaccine activity escape. Our comprehensive review will provide updated information on newly appearing help researchers formulate strategies curtail pandemic.

Язык: Английский

Процитировано

109

COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges DOI Creative Commons
Kuldeep Dhama, Manish Dhawan, Ruchi Tiwari

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2022, Номер 18(5)

Опубликована: Март 8, 2022

Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle COVID-19 pandemic. Most of in use administered via intramuscular (IM) injection, eliciting protective humor cellular immunity. intranasal (IN) also being developed that shown promising ability induce a significant amount antibody-mediated immune response robust cell-mediated immunity as well hold added stimulate mucosal along with additional advantage ease administration compared IM injected vaccines. By inducing secretory IgA antibody responses specifically nasal compartment, SARS-CoV-2 vaccine can prevent virus infection, replication, shedding, disease development, possibly limits transmission. This article highlights current progress, advantages, prospects, challenges developing for countering ongoing

Язык: Английский

Процитировано

78

Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases DOI Creative Commons

Sareh Kakavandi,

Iman Zare, Maryam Vaezjalali

и другие.

Cell Communication and Signaling, Год журнала: 2023, Номер 21(1)

Опубликована: Май 15, 2023

Coronavirus disease 2019 (COVID-19) is caused by a new member of the Coronaviridae family known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are structural and non-structural proteins (NSPs) in genome this virus. S, M, H, E proteins, NSPs include accessory replicase proteins. The NSP components SARS-CoV-2 play an important role its infectivity, some them may be pathogenesis chronic diseases, including cancer, coagulation disorders, neurodegenerative cardiovascular diseases. interact with targets such angiotensin-converting enzyme (ACE2) receptor. In addition, can stimulate pathological intracellular signaling pathways triggering transcription factor hypoxia-inducible factor-1 (HIF-1), neuropilin-1 (NRP-1), CD147, Eph receptors, which roles progression diseases like Alzheimer's disease, epilepsy, multiple sclerosis, cancers glioblastoma, lung malignancies, leukemias. Several compounds polyphenols, doxazosin, baricitinib, ruxolitinib could inhibit these interactions. It has been demonstrated that spike protein stronger affinity for human ACE2 than SARS-CoV, leading current study to hypothesize newly produced variant Omicron receptor-binding domain (RBD) binds more strongly primary strain. SARS Middle East (MERS) viruses against have become resistant previous vaccines. Therefore, review recent studies performance vaccines their effects on COVID-19 related vital need deal conditions. This examines potential initiation it anticipated serve effective vaccine or treatment Video Abstract.

Язык: Английский

Процитировано

66

An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines DOI Open Access
Fatemeh Bayani,

Negin Safaei Hashkavaei,

Sareh Arjmand

и другие.

Progress in Biophysics and Molecular Biology, Год журнала: 2023, Номер 178, С. 32 - 49

Опубликована: Фев. 20, 2023

Язык: Английский

Процитировано

47

Host factors and vaccine efficacy: Implications for COVID‐19 vaccines DOI Open Access
Shahab Falahi, Azra Kenarkoohi

Journal of Medical Virology, Год журнала: 2021, Номер 94(4), С. 1330 - 1335

Опубликована: Ноя. 30, 2021

Abstract The efficacy of the vaccines varies between individuals and populations. immunogenicity vaccine is influenced by various factors, including host factors. Previous studies have shown that factors affect effectiveness vaccines, which may be true about COVID‐19 vaccines. In this review, we evaluate possible association with a special focus on

Язык: Английский

Процитировано

76

Application of digital education in undergraduate nursing and medical interns during the COVID-19 pandemic: A systematic review DOI Open Access
Xiaonan Hao, Xin Peng, Xinxin Ding

и другие.

Nurse Education Today, Год журнала: 2021, Номер 108, С. 105183 - 105183

Опубликована: Окт. 25, 2021

Язык: Английский

Процитировано

66

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review DOI Open Access
Swarnali Das,

Suvrendu Sankar Kar,

Sovan Samanta

и другие.

Immunologic Research, Год журнала: 2022, Номер 70(3), С. 289 - 315

Опубликована: Фев. 22, 2022

Язык: Английский

Процитировано

64